Under the concept that inhibition of acetylcholinesterase (AChE) increases acetylcholine at cholinergic synapses, thus reducing the cognitive deficit [202,203], an approach for the putative treatment of AD is the design and synthesis of MFAs with AChE inhibition activity. Here, ACHE is linked to Alzheimer disease.